Dr Ronan Kelly talks to ecancer about the first results of the CheckMate 577 study, presented at the ESMO 2020 Virtual Meeting.
Adjuvant nivolumab was found to be the first therapeutic to provide a statistically significant and clinically meaningful improvement in disease free survival vs placebo and showed a well tolerated safety profile in patients with resected oesophageal or gastro-oesophageal junction cancer (EC/GEJC), who have received neoadjuvant chemoradiation therapy (CRT).
These results represent the first treatment advance in many years for these patients.
See related news here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.